CCLD vs HCAT

For growth investors, CareCloud, Inc.

(CCLD) is the stronger pick with 8. 7% revenue growth year-over-year, versus 1. 5% for Health Catalyst, Inc. (HCAT). CareCloud, Inc. (CCLD) offers the better valuation at 29. 9x trailing P/E (17. 1x forward), making it the more compelling value choice. Analysts rate CareCloud, Inc. (CCLD) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Health Catalyst, Inc.

is actually cheaper at 14. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, CareCloud, Inc.

(CCLD) delivered a total return of -62. 4%, compared to -96. 9% for Health Catalyst, Inc. (HCAT). Over 10 years, the gap is even starker: CCLD returned +199. 0% versus HCAT's -96. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CareCloud, Inc.

(CCLD) is the lower-risk stock at 1. 15β versus Health Catalyst, Inc. 's 2. 05β — meaning HCAT is approximately 79% more volatile than CCLD relative to the S&P 500. On balance sheet safety, CareCloud, Inc. (CCLD) carries a lower debt/equity ratio of 7% versus 8% for Health Catalyst, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CareCloud, Inc.

(CCLD) is pulling ahead at 8. 7% versus 1. 5% for Health Catalyst, Inc. (HCAT). On earnings-per-share growth, the picture is similar: CareCloud, Inc. grew EPS 135. 7% year-over-year, compared to -121. 7% for Health Catalyst, Inc.. Over a 3-year CAGR, HCAT leads at 4. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CareCloud, Inc.

(CCLD) is the more profitable company, earning 9. 0% net margin versus -57. 2% for Health Catalyst, Inc. — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCLD leads at 9. 5% versus -51. 7% for HCAT. At the gross margin level — before operating expenses — HCAT leads at 48. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Health Catalyst, Inc.

(HCAT) trades at 14. 0x forward P/E versus 17. 1x for CareCloud, Inc. — 3. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HCAT: 59. 2% to $2. 50.

In this comparison, CCLD (0.

6% yield) pays a dividend. HCAT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CareCloud, Inc.

(CCLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 0. 6% yield, +199. 0% 10Y return). Health Catalyst, Inc. (HCAT) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CCLD: +199. 0%, HCAT: -96. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

CCLD pays a dividend while HCAT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.